Cytek Biosciences, Inc. CTKB Intangible asset in accounts payable or accrued expenses at period end
Intangible asset in accounts payable or accrued expenses at period end at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept ctkb:IntangibleAssetInAccruedExpense.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s intangible asset in accounts payable or accrued expenses at period end.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s intangible asset in accounts payable or accrued expenses at period end?
- Cytek Biosciences, Inc. (CTKB) reported intangible asset in accounts payable or accrued expenses at period end of $3K in Q1 2026.
- How has Cytek Biosciences, Inc.'s intangible asset in accounts payable or accrued expenses at period end changed year-over-year?
- Cytek Biosciences, Inc.'s intangible asset in accounts payable or accrued expenses at period end decreased by 93.6% year-over-year, from $47K to $3K.
- What does intangible asset in accounts payable or accrued expenses at period end mean?
- Represents the value of intangible assets acquired or developed that have been recognized as liabilities in accrued expenses but not yet paid in cash. This metric highlights non-cash investing activities and the timing differences between asset acquisition and cash settlement.